BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17598007)

  • 1. Heparin induces mobilization of osteoprotegerin into the circulation.
    Vik A; Brodin E; Sveinbjørnsson B; Hansen JB
    Thromb Haemost; 2007 Jul; 98(1):148-54. PubMed ID: 17598007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment.
    Brodin E; Svensson B; Paulssen RH; Nordoy A; Hansen JB
    J Lab Clin Med; 2004 Nov; 144(5):246-53; discussion 226-7. PubMed ID: 15570242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin.
    Anastassiades E; Lane DA; Ireland H; Flynn A; Curtis JR
    Clin Nephrol; 1989 Dec; 32(6):290-6. PubMed ID: 2558829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
    Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
    Bendetowicz AV; Béguin S; Caplain H; Hemker HC
    Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of unfractionated and low-molecular-weight heparin on OPG, sRANKL, and von Willebrand factor concentrations during hemodialysis.
    Klejna K; Naumnik B; Koc-Żórawska E; Myśliwiec M
    Clin Appl Thromb Hemost; 2014 May; 20(4):433-41. PubMed ID: 23104956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.
    Grimaudo V; Omri A; Kruithof EK; Hauert J; Bachmann F
    Thromb Haemost; 1988 Jun; 59(3):388-91. PubMed ID: 2847348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteers.
    Mismetti P; Reynaud J; Tardy-Ponce B; Laporte-Simitsidis S; Scully M; Goodwyn C; Queneau P; Decousus H
    Thromb Haemost; 1995 Aug; 74(2):660-6. PubMed ID: 8585003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.
    Vila V; Martínez-Sales V; Réganon E; Peris E; Perez F; Ruano M; Aznar J
    Haematologica; 2001 Jul; 86(7):729-34. PubMed ID: 11454528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma--a study in human volunteers.
    Bendetowicz AV; Kai H; Knebel R; Caplain H; Hemker HC; Lindhout T; Béguin S
    Thromb Haemost; 1994 Nov; 72(5):705-12. PubMed ID: 7900078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Low molecular weight heparin: favorable effect profile for prevention and therapy of venous thrombosis].
    Marbet GA
    Ther Umsch; 1992 Dec; 49(12):843-9. PubMed ID: 1336627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of low molecular weight heparin during and after aortic and carotid surgery: dose finding study.
    Alimi YS; Juhan C; Barthelemy P; Boudier JL; Pansart M; Boutin B; De Moro S
    Panminerva Med; 1996 Mar; 38(1):15-21. PubMed ID: 8766874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulant effect at the time of epidural catheter removal in patients receiving twice-daily or once-daily low-molecular-weight heparin and continuous epidural analgesia after orthopedic surgery.
    Douketis JD; Kinnon K; Crowther MA
    Thromb Haemost; 2002 Jul; 88(1):37-40. PubMed ID: 12152674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients.
    Cianciolo G; La Manna G; Donati G; Dormi A; Cappuccilli ML; Cuna V; Legnani C; Palareti G; Colì L; Stefoni S
    Nephrol Dial Transplant; 2011 Feb; 26(2):646-52. PubMed ID: 20659908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R; Grebe S
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Placental transfer of low-molecular weight heparin].
    Schneider D; Heilmann L; Harenberg J
    Geburtshilfe Frauenheilkd; 1995 Feb; 55(2):93-8. PubMed ID: 7758899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.
    Dumaine R; Borentain M; Bertel O; Bode C; Gallo R; White HD; Collet JP; Steinhubl SR; Montalescot G
    Arch Intern Med; 2007 Dec; 167(22):2423-30. PubMed ID: 18071163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low molecular weight heparin and unfractionated heparin are both effective at accelerating pulmonary vascular maturation in neonatal rabbits.
    O'Blenes SB; Merklinger SL; Jegatheeswaran A; Campbell A; Rabinovitch M; Rebeyka I; Van Arsdell G
    Circulation; 2003 Sep; 108 Suppl 1():II161-6. PubMed ID: 12970226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH.
    Alban S; Welzel D; Hemker HC
    Semin Thromb Hemost; 2002 Aug; 28(4):369-78. PubMed ID: 12244484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy.
    Hansen JB; Sandset PM
    Thromb Res; 1998 Aug; 91(4):177-81. PubMed ID: 9736420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.